PMID- 7906158
OWN - NLM
STAT- MEDLINE
DCOM- 19940321
LR  - 20181113
IS  - 1170-229X (Print)
IS  - 1170-229X (Linking)
VI  - 3
IP  - 6
DP  - 1993 Nov-Dec
TI  - Ibopamine. A review of its pharmacodynamic and pharmacokinetic properties, and 
      therapeutic use in congestive heart failure.
PG  - 556-84
AB  - Ibopamine is an orally administered dopamine agonist which is rapidly converted 
      to its active metabolite epinine by esterase hydrolysis. Ibopamine acts 
      predominantly as a vasodilator and inhibitor of neuroendocrine activation in 
      congestive heart failure, but also has mild positive inotropic effects at higher 
      doses. The beneficial effects on cardiac and systemic haemodynamic parameters 
      seen in short term studies have been maintained in predominantly noncomparative 
      trials for up to 1 year, and improvements in New York Heart Association (NYHA) 
      functional class and clinical symptoms have been observed in patients with 
      congestive heart failure of varying severity. In double-blind studies conducted 
      in small numbers of patients, the efficacy of ibopamine was comparable to that of 
      digoxin, captopril, enalapril and hydrochlorothiazide. Ibopamine can successfully 
      replace treatment with intravenous dopamine in patients with severe heart 
      failure, and is effective and well tolerated when administered in combination 
      with digoxin, diuretics and/or angiotensin converting enzyme (ACE) inhibitors. 
      Ibopamine has shown no detrimental effects on renal function, few adverse effects 
      on neurohormonal parameters and has demonstrated no significant proarrhythmic 
      properties at therapeutic doses in patients with congestive heart failure. No 
      adverse metabolic effects were observed during ibopamine therapy in patients with 
      diabetes mellitus, nor did ibopamine have detrimental effects in patients with 
      chronic obstructive pulmonary disease. While reliable evidence is required 
      concerning effects on mortality before the role of ibopamine can be clearly 
      defined, the drug appears to be a useful agent for combination with conventional 
      therapies in treating patients with mild to severe congestive heart failure.
FAU - Spencer, C
AU  - Spencer C
AD  - Adis International Limited, Auckland, New Zealand.
FAU - Faulds, D
AU  - Faulds D
FAU - Fitton, A
AU  - Fitton A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - New Zealand
TA  - Drugs Aging
JT  - Drugs & aging
JID - 9102074
RN  - 0 (Dopamine Agents)
RN  - 8ZCA2I2L11 (ibopamine)
RN  - R7339QLN1C (Deoxyepinephrine)
SB  - IM
MH  - Aged
MH  - Deoxyepinephrine/adverse effects/*analogs & 
      derivatives/pharmacokinetics/pharmacology/therapeutic use
MH  - Dopamine Agents/adverse effects/pharmacokinetics/*pharmacology/therapeutic use
MH  - Heart Failure/*drug therapy
MH  - Humans
RF  - 110
EDAT- 1993/11/01 00:00
MHDA- 1993/11/01 00:01
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 1993/11/01 00:01 [medline]
PHST- 1993/11/01 00:00 [entrez]
AID - 10.2165/00002512-199303060-00008 [doi]
PST - ppublish
SO  - Drugs Aging. 1993 Nov-Dec;3(6):556-84. doi: 10.2165/00002512-199303060-00008.